Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development Anavex Life Sciences Corp AstraZeneca Plc Heptares Therapeutics Ltd Karuna Pharmaceuticals Inc NeuroHealing Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles (aceclidine + tropicamide) - Drug Profile Product Description Mechanism Of Action R&D Progress (ANAVEX-273 + donepezil hydrochloride) - Drug Profile Product Description Mechanism Of Action R&D Progress (trospium chloride + xanomeline tartrate) - Drug Profile Product Description Mechanism Of Action R&D Progress ANAVEX-273 - Drug Profile Product Description Mechanism Of Action R&D Progress Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile Product Description Mechanism Of Action R&D Progress tropicamide - Drug Profile Product Description Mechanism Of Action R&D Progress VU-0467154 - Drug Profile Product Description Mechanism Of Action R&D Progress VU-6000918 - Drug Profile Product Description Mechanism Of Action R&D Progress Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones Featured News & Press Releases May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s disease Patients Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimers Disease Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016 Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016 Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016 Jul 12, 2016: Anavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016 Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Anavex Life Sciences Corp, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by Heptares Therapeutics Ltd, H1 2017 Pipeline by Karuna Pharmaceuticals Inc, H1 2017 Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2017 Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017 List of Figures Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Top 10 Indications, H1 2017 Number of Products by Mechanism of Actions, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Routes of Administration, H1 2017 Number of Products by Stage and Routes of Administration, H1 2017 Number of Products by Stage and Molecule Types, H1 2017

Anavex Life Sciences Corp AstraZeneca Plc Heptares Therapeutics Ltd Karuna Pharmaceuticals Inc NeuroHealing Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd